Delving into the Latest Updates on Institute of Pathogen Biology Chinese Academy of Medical Sciences with Synapse

Overview

Tags

Infectious Diseases

Immune System Diseases

Urogenital Diseases

Chemical drugs

Synthetic peptide

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Infectious Diseases	18
Immune System Diseases	18
Neoplasms	2
Endocrinology and Metabolic Disease	1
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Chemical drugs	6
Small molecule drug	5
Synthetic peptide	5
Recombinant polypeptide	3
Monoclonal antibody	2

Top 5 Target	Count

gp41(Transmembrane glycoprotein gp41)	12
HIV-1 fusion	3
SARS-CoV-2 antigen	2
SARS-CoV-2 S protein	1
CD7(T-cell antigen CD7)	1

主要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的安全性和耐受性。次要目的：评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药效（PD）作用。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的药代动力学（PK）特征。评估在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的免疫原性。探索性目的：探索在未接受过抗病毒治疗的HIV感染者中多次皮下注射LP-98后的病毒学治疗失败的情况。

[Translation]

Primary objective: To evaluate the safety and tolerability of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Secondary objectives: To evaluate the pharmacodynamic (PD) effect of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the pharmacokinetic (PK) characteristics of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. To evaluate the immunogenicity of LP-98 after multiple subcutaneous injections in HIV-infected individuals who have not received antiviral treatment. Exploratory objectives: To explore the failure of virological treatment after multiple subcutaneous injections of LP-98 in HIV-infected individuals who have not received antiviral treatment.

Start Date28 Aug 2024

Sponsor / Collaborator

Institute of Pathogen Biology Chinese Academy of Medical Sciences

[+1]

CTR20233018 / RecruitingPhase 2

评价注射用利普韦肽联合核苷药物在未接受过抗病毒治疗的HIV 感染者中的有效性、安全性的随机、对照、开放、剂量探索临床研究

[Translation] A randomized, controlled, open, dose-finding clinical study to evaluate the efficacy and safety of lepviride for injection combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment

评价注射用利普韦肽联合核苷药物在未接受过抗病毒治疗的HIV 感染者中的有效性、安全性的随机、对照、开放、剂量探索临床研究

[Translation]

A randomized, controlled, open, dose-finding clinical study to evaluate the efficacy and safety of lepviride for injection combined with nucleoside drugs in HIV-infected patients who have not received antiviral treatment

Start Date02 Nov 2023

Sponsor / Collaborator

Institute of Pathogen Biology Chinese Academy of Medical Sciences

[+1]

100 Clinical Results associated with Institute of Pathogen Biology Chinese Academy of Medical Sciences

Login to view more data

0 Patents (Medical) associated with Institute of Pathogen Biology Chinese Academy of Medical Sciences

Login to view more data

2

Literatures (Medical) associated with Institute of Pathogen Biology Chinese Academy of Medical Sciences

01 Mar 2016·Peptide ScienceQ4 · BIOLOGY

Platform technology to generate broadly cross‐reactive antibodies to α‐helical epitopes in hemagglutinin proteins from influenza A viruses

Q4 · BIOLOGY

Article

Author: Shortt, Jonathan A. ; Jiang, Ziqing ; Mant, Colin T. ; Hirsch, Brooke ; Pollock, David D. ; Yan, Zhe ; Qian, Zhaohui ; Hodges, Robert S. ; Holmes, Kathryn V. ; Gera, Lajos

ABSTRACTWe have utilized a de novo designed two‐stranded α‐helical coiled‐coil template to display conserved α‐helical epitopes from the stem region of hemagglutinin (HA) glycoproteins of influenza A. The immunogens have all the surface‐exposed residues of the native α‐helix in the native HA protein of interest displayed on the surface of the two‐stranded α‐helical coiled‐coil template. This template when used as an immunogen elicits polyclonal antibodies which bind to the α‐helix in the native protein. We investigated the highly conserved sequence region 421–476 of HA by inserting 21 or 28 residue sequences from this region into our template. The cross‐reactivity of the resulting rabbit polyclonal antibodies prepared to these immunogens was determined using a series of HA proteins from H1N1, H2N2, H3N2, H5N1, H7N7, and H7N9 virus strains which are representative of Group 1 and Group 2 virus subtypes of influenza A. Antibodies from region 449–476 were Group 1 specific. Antibodies to region 421–448 showed the greatest degree of cross‐reactivity to Group 1 and Group 2 and suggested that this region has a great potential as a “universal” synthetic peptide vaccine for influenza A. © 2016 Wiley Periodicals, Inc. Biopolymers (Pept Sci) 106: 144–159, 2016.

Zhongguo Fanglao Zazhi

Epidemiology and preventive intervention of inactive tuberculosis

Author: Gao Lei ; Xin He-nan ; Zhang Bin ; Zhang Hao-ran ; Du Ying ; Wang Da-kuan ; Jin Qi

China is one of the countries with the highest burden of Mycobacterium tuberculosis(MTB)infection in worldwide with 350 million people were infected as estimated by Dr.Houben and colleagues using Gaussian process regression model.The guidelines on tuberculosis(TB)preventive treatment updated by the World Health Organization in 2020 recommended that "A history of prior TB or TB preventive treatment should not be a contraindication for preventive treatment in case of exposure, following the exclusion of reactivated disease.These individuals, including those with fibrotic radiol. lesions, may be at increased risk of progression."Individuals with chest radiog. abnormalities suggestive of prior healed TB has been recommended as targets for latent tuberculosis infection(LTBI)testing and treatment in American and Canada.In countries and areas with high burden of TB, considering the potential high burden of inactive TB, enhancing active case finding and LTBI preventive treatment in this high-risk group might benefit TB incidence decline in a community level.

100 Deals associated with Institute of Pathogen Biology Chinese Academy of Medical Sciences

Login to view more data

100 Translational Medicine associated with Institute of Pathogen Biology Chinese Academy of Medical Sciences

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 08 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

3

19

Preclinical

Phase 2 Clinical

2

1

Other

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Lipovirtide ( gp41 )	HIV Infections More	Phase 2
LP-98 ( gp41 )	HIV Infections More	Phase 2
LP-40 ( gp41 )	HIV Infections More	Preclinical
LP-97 ( gp41 )	HIV Infections More	Preclinical
LP-83 ( HIV-1 fusion )	HIV Infections More	Preclinical